Everolimus monotherapy (advanced/progressive pNET G1/G2; RADIANT-3)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-EVEROLIMUS`

ID	`REG-EVEROLIMUS-MONO-PNET`
Type	Regimen
Status	reviewed 2026-05-03 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-NET-2025` `SRC-RADIANT3-YAO-2011`

Notes

RADIANT-3 (Yao NEJM 2011): everolimus 10 mg/day vs placebo in progressive well-differentiated pNET (n=410). mPFS 11.0 vs 4.6 mo (HR 0.35, p<0.001). No significant OS benefit demonstrated (confounded by >70% crossover post- progression). SSA prior / concurrent use allowed. Stomatitis prophylaxis (dexamethasone mouthwash, SWISH trial) reduces G2+ stomatitis dramatically. Sunitinib 37.5 mg/day is the alternative (Raymond NEJM 2011 — similar mPFS 11.4 vs 5.5 mo, HR 0.42); no head-to-head comparison; choice based on comorbidities (cardiac/renal → prefer everolimus; diabetes/steroids → consider sunitinib). STUB pending §6.1 signoff.

Used By

Indication

IND-PNET-METASTATIC-1L-EVEROLIMUS - IND-PNET-METASTATIC-1L-EVEROLIMUS

Regimen

REG-SUNITINIB-PHEO - Sunitinib monotherapy (metastatic non-MIBG-avid pheochromocytoma/paraganglioma; FIRSTMAPP...